Get the Stockscreener App
189.24
0.92%
1.73
Revolution Medicines Inc stock is traded at $189.24, with a volume of 3.19M.
It is up +0.92% in the last 24 hours and up +25.07% over the past month.
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.
See More
Previous Close:
$187.51
Open:
$188.37
24h Volume:
3.19M
Relative Volume:
0.95
Market Cap:
$40.23B
Revenue:
$742.00K
Net Income/Loss:
$-1.37B
P/E Ratio:
-26.75
EPS:
-7.0731
Net Cash Flow:
$-1.07B
1W Performance:
+6.21%
1M Performance:
+25.07%
6M Performance:
+139.48%
1Y Performance:
+408.85%
1-Day Range:
$184.28
$189.48
1-Week Range:
$174.26
$193.09
52-Week Range:
$34.00
$193.09
Revolution Medicines Inc Stock (RVMD) Company Profile
Name
Revolution Medicines Inc
Sector
Industry
Phone
650-481-6801
Address
700 SAGINAW DR, REDWOOD CITY, CA
Compare RVMD vs VRTX, REGN, ARGX, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RVMD
Revolution Medicines Inc
|
189.24 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
VRTX
Vertex Pharmaceuticals Inc
|
528.04 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
654.27 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
939.68 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
312.78 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
Revolution Medicines Inc Stock (RVMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-16-26 | Resumed | Jefferies | Buy |
| Feb-27-26 | Resumed | UBS | Buy |
| Nov-18-25 | Initiated | Wolfe Research | Outperform |
| Nov-03-25 | Initiated | RBC Capital Mkts | Outperform |
| Oct-21-25 | Initiated | Mizuho | Outperform |
| Oct-16-25 | Resumed | Stifel | Buy |
| Sep-12-25 | Resumed | Raymond James | Strong Buy |
| Sep-05-25 | Initiated | Truist | Buy |
| Aug-19-25 | Initiated | Piper Sandler | Overweight |
| Aug-15-25 | Initiated | Wells Fargo | Overweight |
| Jul-15-25 | Initiated | Goldman | Buy |
| Jul-16-24 | Reiterated | Needham | Buy |
| Jul-12-24 | Initiated | Barclays | Overweight |
| Jul-08-24 | Initiated | Jefferies | Buy |
| Apr-12-24 | Reiterated | Needham | Buy |
| Apr-10-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Mar-11-24 | Initiated | Piper Sandler | Overweight |
| Jan-05-24 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-04-24 | Initiated | Wedbush | Outperform |
| Nov-16-23 | Initiated | Raymond James | Outperform |
| Feb-28-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-14-22 | Initiated | Needham | Buy |
| Oct-21-22 | Initiated | Oppenheimer | Outperform |
| May-20-22 | Initiated | BofA Securities | Neutral |
| Mar-01-22 | Upgrade | Stifel | Hold → Buy |
| Sep-23-21 | Initiated | Stifel | Hold |
| Aug-12-21 | Downgrade | Goldman | Buy → Neutral |
| May-18-21 | Initiated | Goldman | Buy |
| May-21-20 | Initiated | H.C. Wainwright | Buy |
| Mar-09-20 | Initiated | Cowen | Outperform |
| Mar-09-20 | Initiated | Guggenheim | Buy |
| Mar-09-20 | Initiated | JP Morgan | Neutral |
View All
Revolution Medicines Inc Stock (RVMD) Latest News
Revolution Medicines director Sushil Patel sells $1.05m in stock - Investing.com
Form 4 Revolution Medicines Inc For: 1 July By Investing.com - Investing.com Canada
Revolution Medicines director Sushil Patel sells $1.05m in stock By Investing.com - Investing.com Canada
Revolution Medicines (NASDAQ: RVMD) director sells 5,580 shares, exercises options - Stock Titan
Revolution Medicines Has a $40 Billion Market Cap and Generates No Revenue. Here's Why That's Not Absurd. - Yahoo Finance
Price to sales forward of Revolution Medicines, Inc. – NASDAQ:RVMD - TradingView
Price to earnings forward of Revolution Medicines, Inc. – BMV:RVMD - TradingView
Enterprise value to revenue forward of Revolution Medicines, Inc. – NASDAQ:RVMD - TradingView
Enterprise value to revenue forward of Revolution Medicines, Inc. – MIL:1RVMD - TradingView
Bronstein, Gewirtz & Grossman LLC Urges Erasca, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire Inc.
Price to book forward of Revolution Medicines, Inc. – NASDAQ:RVMD - TradingView
8-Day Rally Sends Revolution Medicines Stock Up 23% - Trefis
Price to earnings forward of Revolution Medicines, Inc. – MIL:1RVMD - TradingView
symbol__ Stock Quote Price and Forecast - CNN
Revolution Medicines Price Target Raised to $235.00/Share From $183.00 by Needham - Moomoo
Revolution Medicines, Inc.(NasdaqGS:RVMD) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Proposed sale of RVMD common shares reported (NASDAQ: RVMD) - Stock Titan
Erasca, Inc. Notice of August 10, 2026 Application Deadline for Class Action LawsuitContact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline - StreetInsider
Revolution Medicines, Inc.(NasdaqGS: RVMD) added to Russell Midcap Growth Benchmark - marketscreener.com
Price to sales forward of Revolution Medicines, Inc. – MIL:1RVMD - TradingView
RVMD Maintained by Needham -- Price Target Raised to $235 - GuruFocus
INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces - GlobeNewswire
Revolution Medicines Is Maintained at Buy by Needham - Moomoo
Stifel Maintains Revolution Medicines(RVMD.US) With Buy Rating, Maintains Target Price $215 - Moomoo
Revolution Medicines, Inc.(NasdaqGS: RVMD) added to Russell 3000E Growth Benchmark - marketscreener.com
Revolution Medicines, Inc.(NasdaqGS: RVMD) added to Russell 1000 Growth Benchmark - marketscreener.com
Revolution Medicines, Inc.(NasdaqGS: RVMD) dropped from Russell 2500 Index - marketscreener.com
Enterprise value to EBITDA forward of Revolution Medicines, Inc. – NASDAQ:RVMD - TradingView
Enterprise value to EBITDA forward of Revolution Medicines, Inc. – TRADEGATE:42Z - TradingView
‘Pharma Bro’ Martin Shkreli Defends Revolution Medicines’ Pancreatic Cancer Study Data: ‘Progress Compounds’ - Stocktwits
Insider Sell: Jack Anders Sells 20,000 Shares of Revolution Medi - GuruFocus
42Z Forecast — Price Target — Prediction for 2027 - TradingView
Revolution Medicines (RVMD) CFO trades 20K shares under 10b5-1 plan - Stock Titan
Revolution Medicines Faces 'Uphill Battle' in Potential Patent Claim Against Erasca, RBC Says - Moomoo
RBC Capital Maintains Revolution Medicines(RVMD.US) With Buy Rating, Maintains Target Price $182 - Moomoo
Revolution Medicines, Inc. Actuals & Estimates (NASDAQ:RVMD) - TradingView
Revolution Medicines, Inc. Actuals & Estimates (BMV:RVMD) - TradingView
Revolution Medicines, Inc. Stock 12‑Month Price Target Raised to $188.57, Implies 11% Upside - TradingView
INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Erasca, Inc. (ERAS) to Contact Law Firm - StreetInsider
Revolution Medicines, Inc. Actuals & Estimates (LSX:A2PYWG) - TradingView
Revolution Medicines rises as investors focus on fresh pancreatic cancer pipeline updates - Quiver Quantitative
J.P. Morgan Maintains Revolution Medicines(RVMD.US) With Buy Rating, Announces Target Price $200 - Moomoo
BofA Securities Maintains Revolution Medicines(RVMD.US) With Buy Rating, Raises Target Price to $212 - Moomoo
Truist Financial Maintains Revolution Medicines(RVMD.US) With Buy Rating - Moomoo
Revolution Medicines to Present Four RAS(ON) Pipeline Studies at 2026 ESMO Gastrointestinal Cancers Congress - Quiver Quantitative
Revolution Medicines to Present Clinical Data from RAS(ON) - GlobeNewswire
Revolution Medicines to Present Clinical Data from RAS(ON) Inhibitor Combination Trials in Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026 - Yahoo! Finance Canada
Form 144 Revolution Medicines For: 24 June By Investing.com - Investing.com Nigeria
A pancreatic cancer drug provides new hope: Five things to know about daraxonrasib - Stanford Medicine
Form 144 | Revolution Medicines(RVMD.US) Officer Proposes to Sell 3.39 Million in Common Stocks - Moomoo
Jack Anders (RVMD) files to sell 20,000 shares after option exercise - Stock Titan
Revolution Medicines Inc Stock (RVMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Revolution Medicines Inc Stock (RVMD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Patel Sushil | Director |
Jun 29 '26 |
Sale |
187.99 |
5,580 |
1,048,967 |
21,656 |
3.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):